A drastic reduction in the total red blood cells
or RBC count or hemoglobin is known as anemia. It can be defined as
the inability to carry optimum amount of oxygen by the blood.
Sickle-cell diseases (SCD) are types of blood disorders which are
usually inherited genetically. One of the common types of SCDs is the
sickle-cell anemia or SCA. It essentially gives rise to an
irregularity in hemoglobin, the protein that carries oxygen in the
blood. Hemoglobin is found typically in the red blood cells of the
body. As a result a sickle-like shaped cell is formed under certain
conditions. Tribulations in sickle cell disease usually start to take
shape at a very early age (within the first year of birth). This
might lead to various health problems including pain attacks also
known as the sickle-cell crisis, swelling in the limbs, microbial
infections, and in certain cases, stroke. Chronic pain may develop
with age. Sickle-cell diseases arise when an individual inherits
abnormal copies of hemoglobin gene from each parent.
According to Center for Disease Control and
Prevention, as of 2016, around 100,000 people in the U.S. are
affected by sickle cell diseases or SCDs. Sickle cell diseases are
very common among black or African Americans. Around 1 in 13 babies
belonging to the race are born with sickle cell diseases. Growing
prevalence of the disease will give rise to an increased demand for
sickle cell disease prevention and cure, thereby augmenting the
growth of the overall sickle cell anemia therapeutics market.
Request a sample copy of this report :
https://www.coherentmarketinsights.com/insight/request-sample/161
Sickle Cell Anemia Therapeutics Market
On the basis of type of medication, the global
market is classified into:
-
Antibiotics
-
Pain-relieving medications
-
Hydroxyurea
-
Others
On the basis of end user, the global market is
classified into:
-
Government
-
Hospitals
-
Private Clinics
-
Others
The National Center for Biotechnology Information
says that sickle cell anemia is one of the most common hereditary
hematological diseases among humans. Annually, around 250,000
children are born with the disease and it is among the most occurring
epidemiological genetic diseases worldwide. Governments around the
world, especially in Africa are taking initiatives to prevent and
cure the disease as a result of which, huge investments on this field
are expected in the coming years. This in turn will encourage the
manufacturers around the world to manufacture in large quantities to
meet the unmet demand thereby propelling the growth of the sickle
cell anemia therapeutics market.
Increasing occurrence of the disease
especially in the Africa region will drive the sickle cell anemia
therapeutics market
According to the World Health Organization, around
5% of the population around the globe carries the gene for the sickle
cell disease. This percentage is as high as 25% in some of the
regions around the world. According to the same report, WHO has
estimated that the occurrence of sickle cell disease is highest in
the African region. To meet this crisis of high prevalence of the
disease, WHO’s governing bodies has taken initiatives to address
the same. Moreover, according to PLOS Medicine, the occurrence of
sickle cell anemia is likely to rise by around 30% by 2050,
especially in the sub-Saharan Africa. This rise in demand will
eventually push the global sickle cell anemia therapeutics market
into a positive growth trajectory over the course of the forecast
period (2016-2024).
There is a growing need of early detection and
prevention of curable diseases especially among the adults. This is
going to be a key opportunity in the market as the percentage of
adult population is increasing on a daily basis owing to the rise in
life expectancy among the global population. Additionally, the demand
for safe and efficacious treatments is gaining prevalence in the
market. This factor coupled with unmet medical needs among the
patients will fuel the growth of the global sickle cell anemia
therapeutics industry.
Request For table of content :
https://www.coherentmarketinsights.com/ongoing-insight/toc/161
Manufacturers around the world are competing on
the availability of technologically advanced drugs for the treatment
of sickle cell anemia. Key players operating in the global sickle
cell anemia therapeutics market are Bristol-Myers Squibb,
GlycoMimetics, Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics,
Inc., Eli Lilly, and Mast Therapeutics.Some of the other
manufacturers are Daiichi Sankyo, Novartis Pharmaceuticals, Bluebird
Bio, HemaQuest Pharmaceuticals Inc., Emmaus Medical, HemaQuest
Pharmaceuticals, Baxter, and Merck Sharp & Dohme.
About Coherent Market Insights:
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
CONTACT US:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel : +1-206-701-6702
No comments:
Post a Comment